Vincerx Pharma Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Vincerx Pharma's earnings have been declining at an average annual rate of -24.1%, while the Biotechs industry saw earnings growing at 19% annually.
Wichtige Informationen
-24.1%
Wachstumsrate der Gewinne
-5.0%
EPS-Wachstumsrate
Biotechs Wachstum der Industrie | 17.0% |
Wachstumsrate der Einnahmen | n/a |
Eigenkapitalrendite | -182.5% |
Netto-Marge | n/a |
Letzte Ertragsaktualisierung | 30 Jun 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Keine Aktualisierungen
Recent updates
Here's Why Vincerx Pharma (NASDAQ:VINC) Must Use Its Cash Wisely
Aug 21Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?
Jul 18Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?
Mar 30Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?
Sep 22Is Vincerx Pharma (NASDAQ:VINC) In A Good Position To Invest In Growth?
Jun 24Vincerx Pharma doses first patient in early-stage VIP152 cancer study
Jun 03Aufschlüsselung der Einnahmen und Ausgaben
Wie Vincerx Pharma Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
---|---|---|---|---|
30 Jun 24 | 0 | -28 | 12 | 18 |
31 Mar 24 | 0 | -38 | 12 | 23 |
31 Dec 23 | 0 | -40 | 14 | 29 |
30 Sep 23 | 0 | -47 | 16 | 35 |
30 Jun 23 | 0 | -54 | 17 | 39 |
31 Mar 23 | 0 | -61 | 18 | 45 |
31 Dec 22 | 0 | -63 | 19 | 50 |
30 Sep 22 | 0 | -58 | 20 | 53 |
30 Jun 22 | 0 | -66 | 21 | 54 |
31 Mar 22 | 0 | -49 | 23 | 51 |
31 Dec 21 | 0 | -39 | 23 | 40 |
30 Sep 21 | 0 | -49 | 20 | 30 |
30 Jun 21 | 0 | -25 | 15 | 18 |
31 Mar 21 | 0 | -23 | 8 | 7 |
31 Dec 20 | 0 | -17 | 4 | 2 |
30 Sep 20 | 0 | 0 | 0 | 0 |
Qualität der Erträge: VINC is currently unprofitable.
Wachsende Gewinnspanne: VINC is currently unprofitable.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: VINC is unprofitable, and losses have increased over the past 5 years at a rate of 24.1% per year.
Beschleunigtes Wachstum: Unable to compare VINC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: VINC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: VINC has a negative Return on Equity (-182.51%), as it is currently unprofitable.